A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- 24 Jun 2016 Status changed from not yet recruiting to recruiting.
- 12 May 2016 Planned number of patients changed from 30 to 31.
- 12 May 2016 Planned initiation date changed from 1 May 2016 to 1 Aug 2016.